Patents by Inventor Bernard Scallon

Bernard Scallon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11078267
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as systemic lupus erythematosus.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: August 3, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Publication number: 20210155711
    Abstract: Antibody and other Fc-containing molecules with variations in the Fc region with reduced binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders.
    Type: Application
    Filed: January 15, 2021
    Publication date: May 27, 2021
    Inventors: Stephen McCarthy, Bernard Scallon, William Strohl, Susan Tam, Omid Vafa
  • Patent number: 10894836
    Abstract: Antibody and other Fc-containing molecules with variations in the Fc region with reduced binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: January 19, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: McCarthy Stephen, Bernard Scallon, William Strohl, Susan Tam, Omid Vafa
  • Publication number: 20200062841
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as systemic lupus erythematosus.
    Type: Application
    Filed: November 7, 2019
    Publication date: February 27, 2020
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Patent number: 10519231
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as systemic lupus erythematosus.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: December 31, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Publication number: 20190248884
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as systemic lupus erythematosus.
    Type: Application
    Filed: February 25, 2019
    Publication date: August 15, 2019
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Patent number: 10259867
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: April 16, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Publication number: 20190085069
    Abstract: An anti-IL-12 antibody or fragment thereof that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody or fragment thereof, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Application
    Filed: December 4, 2018
    Publication date: March 21, 2019
    Inventors: Jill Giles-Komar, George Heavner, David Knight, Jinquan Luo, David Peritt, Bernard Scallon, David Shealy
  • Publication number: 20180334500
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis.
    Type: Application
    Filed: May 1, 2017
    Publication date: November 22, 2018
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Publication number: 20180319893
    Abstract: Antibody and other Fc-containing molecules with variations in the Fc region with reduced binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders.
    Type: Application
    Filed: July 17, 2018
    Publication date: November 8, 2018
    Inventors: McCarthy Stephen, Bernard Scallon, William Strohl, Susan Tam, Omid Vafa
  • Patent number: 10053513
    Abstract: Antibody and other Fc-containing molecules with variations in the Fc region with reduced binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: August 21, 2018
    Assignee: Janssen Biotech, Inc.
    Inventors: Stephen McCarthy, Bernard Scallon, Susan Tam, William Strohl, Omid Vafa
  • Publication number: 20180079809
    Abstract: An anti-IL-12 antibody or fragment thereof that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody or fragment thereof, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Application
    Filed: December 4, 2017
    Publication date: March 22, 2018
    Inventors: Jill Giles-Komar, George Heavner, David Knight, Jinquan Luo, David Peritt, Bernard Scallon, David Shealy
  • Patent number: 9862766
    Abstract: An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: January 9, 2018
    Assignee: Janssen Biotech, inc.
    Inventors: Jill Giles-Komar, George Heavner, David Knight, Jinquan Luo, David Peritt, Bernard Scallon, David Shealy
  • Patent number: 9828424
    Abstract: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: November 28, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
  • Patent number: 9738702
    Abstract: The antibodies, immunoglobulin constructs, or immunoglobulin fusion proteins whose in vivo half-life is increased in ferrets by a modified ferret IgG Fc region can be useful to test therapeutics in ferrets and ferret models.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: August 22, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: Thomas Nesspor, Bernard Scallon
  • Patent number: 9708410
    Abstract: Isolated anti-tissue factor antibodies, immunoglobulins, cleavage products and other specified portions and variants thereof having enhanced ADCC activity, as well as anti-tissue factor antibody compositions, encoding or complementary nucleic acids, vectors, host cells, compositions, formulations, devices, transgenic animals, transgenic plants, and methods of making and using thereof. The antibodies of the invention bind human tissue factor and demonstrate enhanced ADCC activity. Accordingly, the antibodies can be used in a variety of methods for diagnosing, treating, and/or preventing diseases involving tissue factor, where enhanced ADCC activity is desirable such as cancer.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: July 18, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: G. Mark Anderson, Bernard Scallon, Michael Naso, Ann Cai, Cam Holland
  • Patent number: 9676848
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: June 13, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Publication number: 20170157247
    Abstract: An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Application
    Filed: February 14, 2017
    Publication date: June 8, 2017
    Inventors: Jill Giles-Komar, George Heavner, David Knight, Jinquan Luo, David Peritt, Bernard Scallon, David Shealy
  • Patent number: 9605067
    Abstract: An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: March 28, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: Jill Giles-Komar, George Heavner, David Knight, Jinquan Luo, David Peritt, Bernard Scallon, David Shealy
  • Publication number: 20170029496
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis.
    Type: Application
    Filed: June 30, 2016
    Publication date: February 2, 2017
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy